

# Rx Access for Underserved Patients

Association for Accessible Medicines' (AAM) Conference


---

Teva's Global VP for Social Impact & Responsibility  
Amalia Adler-Waxman



# Our SI&R strategy holds us accountable to the people and communities we serve

Our imperative is to contribute to healthy communities and lead with responsible business.



# Teva's product donation programs - integral to our commitment to Access

---

In 2017:



Teva donated **\$82.3M USD** and supported communities across more than **25 countries**



In US alone Teva donated about **4.7 Million units** each year



Teva donated more than **36,000 products** to more than **20,000 patients** through TevaCares Foundation

In the US, Teva's partnered with the top five leading NGOs that promote Access

---



Our partners have been fully vetted, audited and qualified to properly handle, store, distribute and report on the humanitarian Rx donations that we provide.

# Direct Relief has been Teva's principal partner over the past decade

- Teva's medical products have been provided to improve care for the underserved in **86 countries**, including in the United States.
- In total, the wholesale valued of the medicines provided to Direct Relief in the last decade have exceeded **\$1 billion** and impacted **many millions of patients**.

In 2017 alone:

**\$230.6M**  
In medical  
material aid

**199**  
Healthcare  
Providers served

**311**  
Deliveries

Drugs were donated  
from Teva's wide  
range portfolio -  
mainly for Chronic  
Diseases and  
Antibiotics

Calculated according to WAC prices (Wholesale Acquisition Cost )

# Therapeutic classes analysis (2006 - 2018)

Top Five Therapeutic Classes	% of Total Donated
Anti-hyperlipidemic	15.8%
Anti-Infective	21.8%
Other Cardiovascular	18.2%
Hormones	8.5%
Neurological Disorders	11.6%

## Relief to Kerala – India recent floods

Material Description	Shipment Qty	Value
Niacin_500mg_180TAB	200 BT	122,020.00
Amlodipine-Benazepril_5-10mg_500CAP	4 BT	1,493.20
Finasteride_1mg_90TAB	25 BT	538.25



“More than two dozen pallets of medical aid left Direct Relief’s headquarters on Friday morning to support health centers treating communities impacted Among the critically needed relief items were the following products donated by Teva”

# Haiti - how we can make a difference



- Teva supported Haiti via its NGO partners for many years (since 2010 earthquake)
- A continual supply of medicines allows a region to recover and improve over time
- Operation Blessing shared a video that gives a quick glance into the trip of 25 doctors and the impact that we can achieve

# We initiated research to assess this unmet global need and here is what we know:

---

Multiple Chronic Conditions affects:



**1 in 3**  
of all adults



**2 in 3**  
of those 65+

The number of people with MCC is only expected to grow:


The prevalence of MCC is increasing due to several major global trends:

- An aging population
- Improved diagnosis and detection of diseases
- Lifestyle changes
- Environmental issues
- Drug-disease interactions
- Disease-disease interactions



# In 2017, we launched a Signature Initiative on Multiple Chronic Conditions

## Research and advocacy



Commissioned an independent research report on the global state of MCC



Hosted event on MCC with IAPO at 70th WHA in Geneva (May 2017) and shared initial findings from MCC report

## Strategic partnerships



Presented MCC report at World Economic Forum Sustainable Development Impact Summit during UNGA (Sept 2017) and discussed solutions with experts



Established partnership with The Arnhold Institute for Global Health at Mount Sinai to develop scalable, holistic care models to address MCC patient needs

## Scale



- U.S. Social Impact two-year partnership on MCC with Direct Relief and Volunteers in Medicines (2017-2018)
- Expand partnerships geographically
- Align access programs with MCC
- Continue innovating to develop solutions

Thank You.

